技术指导原则-话题@MedSci - williamhill asia

#技术指导原则#

34篇内容 | 1308人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1515199, encodeId=a2161515199db, content=<a href='/topic/show?id=ff10548e973' target=_blank style='color:#2F92EE;'>#技术指导原则#</a>, objectTitle=新规来了！药物临床试验期间方案变更技术指导原则（试行）, objectType=article, longId=730717, objectId=54ebe3071773, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54ebe3071773, replyNumber=0, likeNumber=71, createdTime=2022-06-29, rootId=0, userName=12498a1cm70暂无昵称, userId=3ba310728503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54ebe3071773, moduleTitle=新规来了！药物临床试验期间方案变更技术指导原则（试行）, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=54ebe3071773)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515198, encodeId=3e351515198c3, content=<a href='/topic/show?id=ff10548e973' target=_blank style='color:#2F92EE;'>#技术指导原则#</a>, objectTitle=威廉亚洲博彩公司推荐：体重控制药物临床试验技术指导原则, objectType=article, longId=291930, objectId=66a4291930d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66a4291930d1, replyNumber=0, likeNumber=44, createdTime=2021-12-17, rootId=0, userName=12498a1cm70暂无昵称, userId=3ba310728503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66a4291930d1, moduleTitle=威廉亚洲博彩公司推荐：体重控制药物临床试验技术指导原则, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=66a4291930d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515197, encodeId=7bb9151519e9a, content=<a href='/topic/show?id=ff10548e973' target=_blank style='color:#2F92EE;'>#技术指导原则#</a>, objectTitle=威廉亚洲博彩公司推荐《基因治疗产品非临床研究与评价技术指导原则（试行）》, objectType=article, longId=221822, objectId=6cc1221822e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cc1221822e2, replyNumber=0, likeNumber=48, createdTime=2021-12-12, rootId=0, userName=12498a1cm70暂无昵称, userId=3ba310728503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cc1221822e2, moduleTitle=威廉亚洲博彩公司推荐《基因治疗产品非临床研究与评价技术指导原则（试行）》, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=6cc1221822e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515196, encodeId=007215151969e, content=<a href='/topic/show?id=ff10548e973' target=_blank style='color:#2F92EE;'>#技术指导原则#</a>, objectTitle=威廉亚洲博彩公司推荐：生物标志物在抗肿瘤药物临床研发中应用的技术指导原则, objectType=article, longId=221772, objectId=456e221e72e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=456e221e72e8, replyNumber=0, likeNumber=38, createdTime=2021-12-11, rootId=0, userName=12498a1cm70暂无昵称, userId=3ba310728503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=456e221e72e8, moduleTitle=威廉亚洲博彩公司推荐：生物标志物在抗肿瘤药物临床研发中应用的技术指导原则, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=456e221e72e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515195, encodeId=78b1151519501, content=<a href='/topic/show?id=ff10548e973' target=_blank style='color:#2F92EE;'>#技术指导原则#</a>, objectTitle=《生物标志物在抗肿瘤药物临床研发中应用的技术指导原则》发布, objectType=article, longId=221728, objectId=cf85221e28cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf85221e28cc, replyNumber=0, likeNumber=47, createdTime=2021-12-10, rootId=0, userName=12498a1cm70暂无昵称, userId=3ba310728503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf85221e28cc, moduleTitle=《生物标志物在抗肿瘤药物临床研发中应用的技术指导原则》发布, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=cf85221e28cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515194, encodeId=f82c15151945a, content=<a href='/topic/show?id=ff10548e973' target=_blank style='color:#2F92EE;'>#技术指导原则#</a>, objectTitle=CDE公开征求《人源性干细胞产品药学研究与评价技术指导原则（征求意见稿）》意见, objectType=article, longId=215890, objectId=5635215890ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5635215890ef, replyNumber=0, likeNumber=66, createdTime=2021-08-19, rootId=0, userName=12498a1cm70暂无昵称, userId=3ba310728503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5635215890ef, moduleTitle=CDE公开征求《人源性干细胞产品药学研究与评价技术指导原则（征求意见稿）》意见, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=5635215890ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515193, encodeId=4022151519358, content=<a href='/topic/show?id=ff10548e973' target=_blank style='color:#2F92EE;'>#技术指导原则#</a>, objectTitle=急性淋巴细胞白血病药物临床试验中检测微小残留病的技术指导原则, objectType=article, longId=209942, objectId=434e20994255, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=434e20994255, replyNumber=0, likeNumber=0, createdTime=2021-04-15, rootId=0, userName=12498a1cm70暂无昵称, userId=3ba310728503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=434e20994255, moduleTitle=急性淋巴细胞白血病药物临床试验中检测微小残留病的技术指导原则, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=434e20994255)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515192, encodeId=8cf01515192b0, content=<a href='/topic/show?id=ff10548e973' target=_blank style='color:#2F92EE;'>#技术指导原则#</a>, objectTitle=国家药监局发布，真实世界数据用于医疗器械临床评价技术指导原则（试行）, objectType=article, longId=203785, objectId=9f30203e8509, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f30203e8509, replyNumber=0, likeNumber=53, createdTime=2020-11-28, rootId=0, userName=12498a1cm70暂无昵称, userId=3ba310728503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f30203e8509, moduleTitle=国家药监局发布，真实世界数据用于医疗器械临床评价技术指导原则（试行）, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=9f30203e8509)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515191, encodeId=5535151519109, content=<a href='/topic/show?id=ff10548e973' target=_blank style='color:#2F92EE;'>#技术指导原则#</a>, objectTitle=两类情况药品临床期间即可申请批准！《药品附条件批准上市技术指导原则（试行）》即日实施, objectType=article, longId=203599, objectId=b61720359938, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b61720359938, replyNumber=0, likeNumber=0, createdTime=2020-11-23, rootId=0, userName=12498a1cm70暂无昵称, userId=3ba310728503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b61720359938, moduleTitle=两类情况药品临床期间即可申请批准！《药品附条件批准上市技术指导原则（试行）》即日实施, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=b61720359938)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515190, encodeId=9cf115151909c, content=<a href='/topic/show?id=ff10548e973' target=_blank style='color:#2F92EE;'>#技术指导原则#</a>, objectTitle=CDE发布《中药生物效应检测研究技术指导原则（征求意见稿）》, objectType=article, longId=201493, objectId=981220149313, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=981220149313, replyNumber=0, likeNumber=88, createdTime=2020-10-03, rootId=0, userName=12498a1cm70暂无昵称, userId=3ba310728503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=981220149313, moduleTitle=CDE发布《中药生物效应检测研究技术指导原则（征求意见稿）》, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=981220149313)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515189, encodeId=839f151518929, content=<a href='/topic/show?id=ff10548e973' target=_blank style='color:#2F92EE;'>#技术指导原则#</a>, objectTitle=CSCO 2020丨张虹：解读抗肿瘤新药技术指导原则, objectType=article, longId=200998, objectId=6044200998a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6044200998a0, replyNumber=0, likeNumber=51, createdTime=2020-09-23, rootId=0, userName=12498a1cm70暂无昵称, userId=3ba310728503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6044200998a0, moduleTitle=CSCO 2020丨张虹：解读抗肿瘤新药技术指导原则, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=6044200998a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515188, encodeId=304c15151880c, content=<a href='/topic/show?id=ff10548e973' target=_blank style='color:#2F92EE;'>#技术指导原则#</a>, objectTitle=CDE发布《基因治疗产品药学研究与评价技术指导原则（征求意见稿）》, objectType=article, longId=200722, objectId=ba17200e22cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba17200e22cb, replyNumber=0, likeNumber=87, createdTime=2020-09-17, rootId=0, userName=12498a1cm70暂无昵称, userId=3ba310728503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba17200e22cb, moduleTitle=CDE发布《基因治疗产品药学研究与评价技术指导原则（征求意见稿）》, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=ba17200e22cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515187, encodeId=cde4151518e62, content=<a href='/topic/show?id=ff10548e973' target=_blank style='color:#2F92EE;'>#技术指导原则#</a>, objectTitle=群体药代研究技术指导原则征求意见稿, objectType=article, longId=198696, objectId=d747198696a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d747198696a2, replyNumber=0, likeNumber=87, createdTime=2020-08-05, rootId=0, userName=12498a1cm70暂无昵称, userId=3ba310728503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d747198696a2, moduleTitle=群体药代研究技术指导原则征求意见稿, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=d747198696a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515186, encodeId=ba881515186c8, content=<a href='/topic/show?id=ff10548e973' target=_blank style='color:#2F92EE;'>#技术指导原则#</a>, objectTitle=关于公开征求《抗肿瘤药联合治疗临床试验技术指导原则》意见的通知, objectType=article, longId=197705, objectId=a79a19e70511, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a79a19e70511, replyNumber=0, likeNumber=63, createdTime=2020-07-19, rootId=0, userName=12498a1cm70暂无昵称, userId=3ba310728503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a79a19e70511, moduleTitle=关于公开征求《抗肿瘤药联合治疗临床试验技术指导原则》意见的通知, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=a79a19e70511)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515185, encodeId=6997151518505, content=<a href='/topic/show?id=ff10548e973' target=_blank style='color:#2F92EE;'>#技术指导原则#</a>, objectTitle=关于公开征求《抗急性淋巴细胞白血病药物临床试验中检测微小残留病的技术指导原则（征求意见稿）》意见的通知, objectType=article, longId=194212, objectId=13c2194212aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13c2194212aa, replyNumber=0, likeNumber=0, createdTime=2020-05-17, rootId=0, userName=12498a1cm70暂无昵称, userId=3ba310728503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13c2194212aa, moduleTitle=关于公开征求《抗急性淋巴细胞白血病药物临床试验中检测微小残留病的技术指导原则（征求意见稿）》意见的通知, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=13c2194212aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515184, encodeId=f7d4151518408, content=<a href='/topic/show?id=ff10548e973' target=_blank style='color:#2F92EE;'>#技术指导原则#</a>, objectTitle=关于《社区获得性细菌性肺炎抗菌药物研发临床试验技术指导原则》和《急性细菌性皮肤与皮肤结构感染抗菌药物研发临床试验技术指导原则》征求意见的通知, objectType=article, longId=190910, objectId=dce919091038, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dce919091038, replyNumber=0, likeNumber=60, createdTime=2020-03-28, rootId=0, userName=12498a1cm70暂无昵称, userId=3ba310728503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dce919091038, moduleTitle=关于《社区获得性细菌性肺炎抗菌药物研发临床试验技术指导原则》和《急性细菌性皮肤与皮肤结构感染抗菌药物研发临床试验技术指导原则》征求意见的通知, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=dce919091038)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515183, encodeId=c849151518371, content=<a href='/topic/show?id=ff10548e973' target=_blank style='color:#2F92EE;'>#技术指导原则#</a>, objectTitle=【NMPA】公开征求《真实世界数据用于医疗器械临床评价技术指导原则》意见, objectType=article, longId=185449, objectId=85f918544935, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85f918544935, replyNumber=0, likeNumber=51, createdTime=2020-01-01, rootId=0, userName=12498a1cm70暂无昵称, userId=3ba310728503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85f918544935, moduleTitle=【NMPA】公开征求《真实世界数据用于医疗器械临床评价技术指导原则》意见, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=85f918544935)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515182, encodeId=e48a151518261, content=<a href='/topic/show?id=ff10548e973' target=_blank style='color:#2F92EE;'>#技术指导原则#</a>, objectTitle=晚期非小细胞肺癌临床试验终点技术指导原则发布, objectType=article, longId=179732, objectId=76671e973221, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76671e973221, replyNumber=0, likeNumber=68, createdTime=2019-09-21, rootId=0, userName=12498a1cm70暂无昵称, userId=3ba310728503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76671e973221, moduleTitle=晚期非小细胞肺癌临床试验终点技术指导原则发布, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=76671e973221)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515181, encodeId=a7a615151811b, content=<a href='/topic/show?id=ff10548e973' target=_blank style='color:#2F92EE;'>#技术指导原则#</a>, objectTitle=CDE公开征求《晚期非小细胞肺癌临床试验终点技术指导原则（征求意见稿）》意见, objectType=article, longId=172188, objectId=5ba91e218836, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ba91e218836, replyNumber=0, likeNumber=60, createdTime=2019-06-27, rootId=0, userName=12498a1cm70暂无昵称, userId=3ba310728503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ba91e218836, moduleTitle=CDE公开征求《晚期非小细胞肺癌临床试验终点技术指导原则（征求意见稿）》意见, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=5ba91e218836)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515180, encodeId=8bdf1515180ee, content=<a href='/topic/show?id=ff10548e973' target=_blank style='color:#2F92EE;'>#技术指导原则#</a>, objectTitle=已上市抗肿瘤药物增加新适应症技术指导原则, objectType=article, longId=155111, objectId=18ff1551117c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18ff1551117c, replyNumber=0, likeNumber=60, createdTime=2018-12-06, rootId=0, userName=12498a1cm70暂无昵称, userId=3ba310728503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18ff1551117c, moduleTitle=已上市抗肿瘤药物增加新适应症技术指导原则, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=18ff1551117c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

技术指导原则

2020-05-29

12498a1cm70暂无昵称 (审核中...)

前往app查看评论内容

#技术指导原则#

新规来了！药物临床试验期间方案变更技术指导原则（试行）

2022-06-29

12498a1cm70暂无昵称 (审核中...)

前往app查看评论内容

#技术指导原则#

威廉亚洲博彩公司推荐：体重控制药物临床试验技术指导原则

2021-12-17

12498a1cm70暂无昵称 (审核中...)

前往app查看评论内容

#技术指导原则#

威廉亚洲博彩公司推荐《基因治疗产品非临床研究与评价技术指导原则（试行）》

2021-12-12

12498a1cm70暂无昵称 (审核中...)

前往app查看评论内容

#技术指导原则#

威廉亚洲博彩公司推荐：生物标志物在抗肿瘤药物临床研发中应用的技术指导原则

2021-12-11

12498a1cm70暂无昵称 (审核中...)

前往app查看评论内容

#技术指导原则#

《生物标志物在抗肿瘤药物临床研发中应用的技术指导原则》发布

2021-12-10

12498a1cm70暂无昵称 (审核中...)

前往app查看评论内容

#技术指导原则#

CDE公开征求《人源性干细胞产品药学研究与评价技术指导原则（征求意见稿）》意见

2021-08-19

12498a1cm70暂无昵称 (审核中...)

前往app查看评论内容

#技术指导原则#

急性淋巴细胞白血病药物临床试验中检测微小残留病的技术指导原则

2021-04-15

12498a1cm70暂无昵称 (审核中...)

前往app查看评论内容

#技术指导原则#

国家药监局发布，真实世界数据用于医疗器械临床评价技术指导原则（试行）

2020-11-28

12498a1cm70暂无昵称 (审核中...)

前往app查看评论内容

#技术指导原则#

两类情况药品临床期间即可申请批准！《药品附条件批准上市技术指导原则（试行）》即日实施

2020-11-23

12498a1cm70暂无昵称 (审核中...)

前往app查看评论内容

#技术指导原则#

CDE发布《中药生物效应检测研究技术指导原则（征求意见稿）》

2020-10-03

12498a1cm70暂无昵称 (审核中...)

前往app查看评论内容

#技术指导原则#

CSCO 2020丨张虹：解读抗肿瘤新药技术指导原则

2020-09-23

12498a1cm70暂无昵称 (审核中...)

前往app查看评论内容

#技术指导原则#

CDE发布《基因治疗产品药学研究与评价技术指导原则（征求意见稿）》

2020-09-17

12498a1cm70暂无昵称 (审核中...)

前往app查看评论内容

#技术指导原则#

群体药代研究技术指导原则征求意见稿

2020-08-05

12498a1cm70暂无昵称 (审核中...)

前往app查看评论内容

#技术指导原则#

关于公开征求《抗肿瘤药联合治疗临床试验技术指导原则》意见的通知

2020-07-19

12498a1cm70暂无昵称 (审核中...)

前往app查看评论内容

#技术指导原则#

关于公开征求《抗急性淋巴细胞白血病药物临床试验中检测微小残留病的技术指导原则（征求意见稿）》意见的通知

2020-05-17

12498a1cm70暂无昵称 (审核中...)

前往app查看评论内容

#技术指导原则#

关于《社区获得性细菌性肺炎抗菌药物研发临床试验技术指导原则》和《急性细菌性皮肤与皮肤结构感染抗菌药物研发临床试验技术指导原则》征求意见的通知

2020-03-28

12498a1cm70暂无昵称 (审核中...)

前往app查看评论内容

#技术指导原则#

【NMPA】公开征求《真实世界数据用于医疗器械临床评价技术指导原则》意见

2020-01-01

12498a1cm70暂无昵称 (审核中...)

前往app查看评论内容

#技术指导原则#

晚期非小细胞肺癌临床试验终点技术指导原则发布

2019-09-21

12498a1cm70暂无昵称 (审核中...)

前往app查看评论内容

#技术指导原则#

CDE公开征求《晚期非小细胞肺癌临床试验终点技术指导原则（征求意见稿）》意见

2019-06-27

12498a1cm70暂无昵称 (审核中...)

前往app查看评论内容

#技术指导原则#

已上市抗肿瘤药物增加新适应症技术指导原则

2018-12-06

科室
- - 订阅+
  - 更多科室
工具
服务